WO1999034006A3 - Methode de selection positive de cellules t cd4+ transduites avec des genes anti-vih - Google Patents

Methode de selection positive de cellules t cd4+ transduites avec des genes anti-vih Download PDF

Info

Publication number
WO1999034006A3
WO1999034006A3 PCT/EP1998/008395 EP9808395W WO9934006A3 WO 1999034006 A3 WO1999034006 A3 WO 1999034006A3 EP 9808395 W EP9808395 W EP 9808395W WO 9934006 A3 WO9934006 A3 WO 9934006A3
Authority
WO
WIPO (PCT)
Prior art keywords
lymphocytes
positive selection
hiv
hiv genes
lymphocytes transduced
Prior art date
Application number
PCT/EP1998/008395
Other languages
English (en)
Other versions
WO1999034006A2 (fr
Inventor
Claudio Bordignon
Original Assignee
Genera Spa
Claudio Bordignon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genera Spa, Claudio Bordignon filed Critical Genera Spa
Priority to AU24159/99A priority Critical patent/AU2415999A/en
Publication of WO1999034006A2 publication Critical patent/WO1999034006A2/fr
Publication of WO1999034006A3 publication Critical patent/WO1999034006A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des cellules T CD4+ génétiquement modifiées pour exprimer un marqueur de surface cellulaire et capables de subir une infection par VIH dans des systèmes in vivo et in vitro. L'invention concerne également une méthode de sélection positive de cellules T CD4+, produisant une population totalement apte à une infection par VIH ou par un autre rétrovirus ou d'autres vecteurs rétroviraux, ce qui permet d'effectuer une transduction de cellules mononucléaires sanguines périphériques ou de cellules T CD4+.
PCT/EP1998/008395 1997-12-23 1998-12-22 Methode de selection positive de cellules t cd4+ transduites avec des genes anti-vih WO1999034006A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU24159/99A AU2415999A (en) 1997-12-23 1998-12-22 A method for the positive selection of cd4+ t-lymphocytes transduced with anti-hiv genes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI972866 IT1297016B1 (it) 1997-12-23 1997-12-23 Processo di selezione di linfociti t cd4+ per la transduzione di geni anti-hiv
ITMI97A02866 1997-12-23

Publications (2)

Publication Number Publication Date
WO1999034006A2 WO1999034006A2 (fr) 1999-07-08
WO1999034006A3 true WO1999034006A3 (fr) 1999-09-02

Family

ID=11378447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/008395 WO1999034006A2 (fr) 1997-12-23 1998-12-22 Methode de selection positive de cellules t cd4+ transduites avec des genes anti-vih

Country Status (3)

Country Link
AU (1) AU2415999A (fr)
IT (1) IT1297016B1 (fr)
WO (1) WO1999034006A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1088892A1 (fr) * 1999-09-24 2001-04-04 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Phages récombinantes capable d'entrer dans des cellules hôtes par liaison avec un récepteur artificial
US6479280B1 (en) * 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021806A1 (fr) * 1993-03-19 1994-09-29 Medical Research Council Systeme d'administration commande par des facteurs associes au vih et a la cellule
WO1995006723A1 (fr) * 1993-09-01 1995-03-09 Boehringer Mannheim Gmbh Procede de marquage de cellules eucariotes par utilisation d'un recepteur de surface cellulaire en tant que marqueur
WO1996004386A1 (fr) * 1994-08-05 1996-02-15 Warner-Lambert Company Procede d'utilisation d'une integrase retrovirale negative transdominante dans le traitement d'infection retrovirale
EP0759471A1 (fr) * 1994-05-10 1997-02-26 Hisamitsu Pharmaceutical Co., Inc. Vecteur recombinant du virus de l'immunodeficience humaine et procede pour sa production
WO1998017308A1 (fr) * 1996-10-25 1998-04-30 Immusol Incorporated Inhibition de l'infection par le vih par clivage de l'arn co-recepteur

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021806A1 (fr) * 1993-03-19 1994-09-29 Medical Research Council Systeme d'administration commande par des facteurs associes au vih et a la cellule
WO1995006723A1 (fr) * 1993-09-01 1995-03-09 Boehringer Mannheim Gmbh Procede de marquage de cellules eucariotes par utilisation d'un recepteur de surface cellulaire en tant que marqueur
EP0759471A1 (fr) * 1994-05-10 1997-02-26 Hisamitsu Pharmaceutical Co., Inc. Vecteur recombinant du virus de l'immunodeficience humaine et procede pour sa production
WO1996004386A1 (fr) * 1994-08-05 1996-02-15 Warner-Lambert Company Procede d'utilisation d'une integrase retrovirale negative transdominante dans le traitement d'infection retrovirale
WO1998017308A1 (fr) * 1996-10-25 1998-04-30 Immusol Incorporated Inhibition de l'infection par le vih par clivage de l'arn co-recepteur

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BENATI, C. ET AL.: "Intracellular immunization for the treatment of HIV infection: a new rapid method to transduce and select primary human T-lymphocytes", GENE THERAPY, vol. 2, no. Suppl.1, 1995, pages S30 - Abstr.111a, XP002105245 *
BONA, R. ET AL.: "Aberrant, noninfectious HIV-1 particles are released by chronically infected human T cells transduced with a retroviral vector expressing an interfering HIV-1 variant.", GENE THERAPY, vol. 4, no. 10, October 1997 (1997-10-01), pages 1085 - 92, XP002105246 *
BORDIGNON C ET AL: "Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation", HUMAN GENE THERAPY, vol. 6, no. 6, June 1995 (1995-06-01), pages 813 - 819, XP002100641 *
MALIM M H ET AL: "FUNCTIONAL DISSECTION OF THE HIV-1 REV TRANS-ACTIVATOR-DERIVATION OF A TRANS-DOMINANT REPRESSOR OF REV FUNCTION", CELL, vol. 58, no. 1, 14 July 1989 (1989-07-14), pages 205 - 214, XP000050691 *
TURCHETTO, L. ET AL.: "An approach to HIV gene therapy by transduction of multifunctional retroviral vectors in primary human T lymphocytes.", JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS., vol. 11, no. 1/2, January 1997 (1997-01-01) - June 1997 (1997-06-01), pages 79 - 81, XP002105247 *

Also Published As

Publication number Publication date
ITMI972866A1 (it) 1999-06-23
IT1297016B1 (it) 1999-08-03
WO1999034006A2 (fr) 1999-07-08
AU2415999A (en) 1999-07-19

Similar Documents

Publication Publication Date Title
BG103334A (en) Antiviral vectors
GB2325003A (en) Rectroviral vectors
CA2328404A1 (fr) Nouvelles cellules lentivirales d'encapsidation
AU2998597A (en) Crossless retroviral vectors
WO1995030763A3 (fr) Vecteurs retroviraux a taux de recombinaison reduit
AU3725689A (en) Expression of retrovirus gag protein in eukaryotic cells
WO1997007225A3 (fr) Systeme hautement efficace d'encapsidation retrovirale
HUP9901790A2 (hu) Kationos viroszómák mint genetikai anyag bevitelére alkalmas rendszerek
ATE292983T1 (de) Chimäres retrovirus/adenovirus system
TR199801395A2 (xx) Genetik olarak de�i�tirilmi� h�creler ve bunlar�n kullan�mlar�.
WO2000061617A3 (fr) Cellules transitoirement immortalisees pour therapie genique
EP0759471A4 (fr) Vecteur recombinant du virus de l'immunodeficience humaine et procede pour sa production
CA2311641A1 (fr) Vecteurs retroviraux pseudotypes a proteines de surface d'enveloppe et procede de fabrication desdits vecteurs pour le transfert selectif de genes
AU3258295A (en) Retroviral vector hybrids and the use thereof for gene transfer
WO1999034006A3 (fr) Methode de selection positive de cellules t cd4+ transduites avec des genes anti-vih
AU7028998A (en) Retroviral vectors, method for the production and the use thereof for gene transfer in cd4-positive cells
EP0801575A4 (fr) Vecteurs retroviraux destines a l'expression dans les cellules embryonnaires
AU4193289A (en) Retroviral vectors expressing soluble cd4: a gene therapy for aids
AU5557196A (en) High efficiency ex vivo transduction of hematopoietic stem cells by recombinant retroviral preparations
AU7345500A (en) Identification of the domain of plasmodium falciparum erythrocyte membrane protein 1 (pfemp1) that mediates adhesion to chondroitin sulfate
AU1711088A (en) Hiv related human retrovirus strain with cloned nucleotide sequence and applications thereof
EP0276591A3 (en) Viral vector and recombinant dna coding for the p25 protein of the aids virus
WO1999027123A3 (fr) Vecteurs viraux sv40 modifies
CA2306634A1 (fr) Lignees de cellules d'encapsidation en suspension pour vecteurs retroviraux
RU95122192A (ru) Сем-к - штамм перевиваемых клеток человека, устойчивый к вич-инфекции

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase